Neuroplasticity in the use of a human glucone-like peptide-1 analog in an obese patient: clinical case
- Autores: Matveeva M.1, Samoilova Y.1, Oleynik O.1, Kudlay D.2,3, Podchinenova D.1, Apalkov D.1
-
Afiliações:
- Siberian State Medical University, Ministry of Health of Russia
- I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
- M.V. Lomonosov Moscow State University
- Edição: Volume 34, Nº 11 (2023)
- Páginas: 75-78
- Seção: From Practice
- URL: https://journals.rcsi.science/0236-3054/article/view/249516
- DOI: https://doi.org/10.29296/25877305-2023-11-18
- ID: 249516
Citar
Resumo
This clinical case reflects a variety of symptoms in obesity with central nervous system involvement. At the same time, the use of liraglutide in an obese patient resulted not only in the reduction of visceral fat area, but also in the improvement of cognitive functions, reduction of neuropilin, and as a consequence, reversibility of neurometabolism and functional changes in the brain. Literature sources from international and Russian databases for 5 years were used to compare the results.
Palavras-chave
Texto integral
##article.viewOnOriginalSite##Sobre autores
M. Matveeva
Siberian State Medical University, Ministry of Health of Russia
Email: oleynikoa@mail.ru
ORCID ID: 0000-0001-9966-6686
Professor, MD
Rússia, TomskYu. Samoilova
Siberian State Medical University, Ministry of Health of Russia
Email: oleynikoa@mail.ru
ORCID ID: 0000-0002-2667-4842
Professor, MD
Rússia, TomskO. Oleynik
Siberian State Medical University, Ministry of Health of Russia
Email: oleynikoa@mail.ru
ORCID ID: 0000-0002-2915-384X
Candidate of Medical Sciences
Rússia, TomskD. Kudlay
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia; M.V. Lomonosov Moscow State University
Email: oleynikoa@mail.ru
ORCID ID: 0000-0003-1878-4467
Professor, Corresponding member of the Russian Academy of Sciences, MD
Rússia, Moscow; MoscowD. Podchinenova
Siberian State Medical University, Ministry of Health of Russia
Autor responsável pela correspondência
Email: oleynikoa@mail.ru
ORCID ID: 0000-0001-6212-4568
Candidate of Medical Sciences
Rússia, TomskD. Apalkov
Siberian State Medical University, Ministry of Health of Russia
Email: oleynikoa@mail.ru
Rússia, Tomsk
Bibliografia
- Mayoral L.P., Andrade G.M., Mayoral E.P. et al. Obesity subtypes, related biomarkers & heterogeneity. Indian J Med Res. 2020; 151 (1): 11–21. doi: 10.4103/ijmr.IJMR_1768_17
- Hruby A., Hu F.B. The Epidemiology of Obesity: A Big Picture. Pharmacoeconomics. 2015; 33 (7): 673–89. doi: 10.1007/s40273-014-0243-x
- Ortega F.B., Mora-Gonzalez J., Cadenas-Sanchez C. et al. Effects of an Exercise Program on Brain Health Outcomes for Children With Overweight or Obesity: The ActiveBrains Randomized Clinical Trial. JAMA Netw Open. 2022; 5 (8): e2227893. doi: 10.1001/jamanetworkopen.2022.27893
- Selman A., Burns S., Reddy A.P. et al. The Role of Obesity and Diabetes in Dementia. Int J Mol Sci. 2022; 23 (16): 9267. doi: 10.3390/ijms23169267
- Benomar Y., Taouis M. Molecular Mechanisms Underlying Obesity-Induced Hypothalamic Inflammation and Insulin Resistance: Pivotal Role of Resistin/TLR4 Pathways. Front Endocrinol (Lausanne). 2019; 10: 140. doi: 10.3389/fendo.2019.00140
- Flores-Cordero J.A., Pérez-Pérez A., Jiménez-Cortegana C. et al. Obesity as a Risk Factor for Dementia and Alzheimer's Disease: The Role of Leptin. Int J Mol Sci. 2022; 23 (9): 5202. doi: 10.3390/ijms23095202
- Cui Q.N., Stein L.M., Fortin S.M. et al. The role of glia in the physiology and pharmacology of glucagon-like peptide-1: implications for obesity, diabetes, neurodegeneration and glaucoma. Br J Pharmacol. 2022; 179 (4): 715–26. doi: 10.1111/bph.15683
- Nakanishi Y., Kang S., Kumanogoh A. Axon guidance molecules in immunometabolic diseases. Inflamm Regen. 2022; 42 (1): 5. doi: 10.1186/s41232-021-00189-0
- Al-Thomali A.W., Al-Kuraishy H.M., Al-Gareeb A.I. et al. Role of Neuropilin 1 in COVID-19 Patients with Acute Ischemic Stroke. Biomedicines. 2022; 10 (8): 2032. doi: 10.3390/biomedicines10082032
- Дедов И.И., Шестакова М.В., Мельниченко Г.А. и др. Междисциплинарные клинические рекомендации «Лечение ожирения и коморбидных заболеваний». Ожирение и метаболизм. 2021; 18 (1): 5–99 [Dedov I.I., Shestakova M.V., Melnichenko G.A. et al. Interdisciplinary clinical practice guidelines "Management of obesity and its comorbidities". Obesity and metabolism. 2021; 18 (1): 5–99 (in Russ.)]. doi: 10.14341/omet12714
- Caballero B. Humans against Obesity: Who Will Win? Adv Nutr. 2019; 10 (suppl_1): S4–S9. doi: 10.1093/advances/nmy055
- Melchior V., Fuchs S., Scantamburlo G. Vignette thérapeutique de l’étudiant. Obésité et troubles du comportement alimentaire [Obesity and eating disorders]. Rev Med Liege. 2021; 76 (2): 134–9 (in French).
- Ho Y.C., Srinivasan R.S. Lymphatic Vasculature in Energy Homeostasis and Obesity. Front Physiol. 2020; 11: 3. doi: 10.3389/fphys.2020.00003
- Song S., Guo R., Mehmood A. et al. Liraglutide attenuate central nervous inflammation and demyelination through AMPK and pyroptosis-related NLRP3 pathway. CNS Neurosci Ther. 2022; 28 (3): 422–34. doi: 10.1111/cns.13791
- Drucker D.J. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022; 57: 101351. doi: 10.1016/j.molmet.2021.101351
- Knudsen L.B., Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019; 10: 155. doi: 10.3389/fendo.2019.00155
- Varkevisser R.D.M., van Stralen M.M., Kroeze W. et al. Determinants of weight loss maintenance: a systematic review. Obes Rev. 2019; 20 (2): 171–211. doi: 10.1111/obr.12772
- Val-Laillet D., Aarts E., Weber B. et al. Neuroimaging and neuromodulation approaches to study eating behavior and prevent and treat eating disorders and obesity. Neuroimage Clin. 2015; 8: 1–31. doi: 10.1016/j.nicl.2015.03.016